TNXP Tonix Pharmaceuticals Holding Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TNXP

Price (delayed)

$10.24

Market cap

$175.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.11

Enterprise value

$666,486

?
Relative Growth: Rel. Growth: 37
Relative Strength: Rel. Strength: 10
Relative Valuation: Rel. Valuation: 11
Relative Profitability: Rel. Profitability: 17

* Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central ...

Highlights
The company's revenue has surged by 196% YoY and by 66% QoQ
TNXP's gross margin has soared by 186% YoY and by 43% from the previous quarter
TNXP's EPS has plunged by 105% YoY but it is up by 10% from the previous quarter
The company's equity rose by 32% YoY but it fell by 2.1% QoQ
The debt has surged by 159% year-on-year
The net income has dropped by 96% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tonixpharma.com
Peers: SCYX ANIP UTHR

Key stats

What are the main financial stats of TNXP

TNXP stock price

How has the Tonix Pharmaceuticals Holding stock price performed over time
Intraday
-3.31%
1 week
-12.93%
1 month
-18.41%
1 year
-59.51%
YTD
-34.44%
QTD
-19.75%

Financial performance

How have Tonix Pharmaceuticals Holding's revenue and profit performed over time
Revenue
$29.1M
Gross profit
$24.4M
Operating income
-$165.43M
Net income
-$159.67M
Gross margin
83.8%
Net margin
-548.6%
The company's revenue has surged by 196% YoY and by 66% QoQ
TNXP's gross margin has soared by 186% YoY and by 43% from the previous quarter
The gross profit has soared by 137% from the previous quarter
Tonix Pharmaceuticals Holding's operating income has plunged by 101% YoY and by 9% from the previous quarter

Price vs fundamentals

How does TNXP's price correlate with its fundamentals

Growth

What is Tonix Pharmaceuticals Holding's growth rate over time

Valuation

What is Tonix Pharmaceuticals Holding stock price valuation
P/E
N/A
P/B
0.73
P/S
5.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.02
TNXP's EPS has plunged by 105% YoY but it is up by 10% from the previous quarter
The P/B is 52% higher than the 5-year quarterly average of 0.5 but 16% lower than the last 4 quarters average of 0.9
The company's equity rose by 32% YoY but it fell by 2.1% QoQ
The company's revenue has surged by 196% YoY and by 66% QoQ
TNXP's P/S is 51% below its last 4 quarters average of 12.3

Efficiency

How efficient is Tonix Pharmaceuticals Holding business performance
TNXP's return on invested capital has dropped by 135% year-on-year and by 5% since the previous quarter
TNXP's ROS is up by 35% from the previous quarter and by 33% YoY
TNXP's ROA is down by 20% YoY
The company's return on equity fell by 19% YoY

Dividends

What is TNXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TNXP.

Financial health

How did Tonix Pharmaceuticals Holding financials performed over time
Tonix Pharmaceuticals Holding's total liabilities has soared by 64% YoY and by 3.4% from the previous quarter
The total assets has grown by 36% YoY
The debt is 99% smaller than the equity
The debt has surged by 159% year-on-year
The company's equity rose by 32% YoY but it fell by 2.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.